Evidence map›Paper›PMID 32623632›Full record

ArticleHepatology international2020

Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study).

Shiv Kumar Sarin, Ashok Choudhury, George K Lau, Ming-Hua Zheng, Dong Ji, Sherief Abd-Elsalam, Jaeseok Hwang, Xiaolong Qi, Ian Homer Cua, Jeong Ill Suh and 38 more

2 registry-linked trialsOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatology international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 166 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
166citing papers in PubMed, 6 pooled it
36.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04883177 completednot on this mapstarted 2021, after this paper: background citation

Effectiveness and Safety of the COVID-19 Vaccination for Patients With Liver Disease (CHESS2101): a Multicenter Cohort Study

TypeobservationalSponsorHepatopancreatobiliary Surgery Institute of Gansu ProvinceRan2021 to 2022Enrolled1,000ConditionsCOVID-19, Liver Disease, Vaccine Reaction
NCT05204602 unknown statusnot on this mapstarted 2022, after this paper: background citation

Safety and Immunogenicity of Third Dose SARS-CoV-2 Vaccine Booster in Patients With Liver Diseases Following Two Doses of Inactivated Vaccines (NMCID-CHESS 2201): a Multicenter Cohort Study

TypeobservationalSponsorHuashan HospitalRan2022 to 2022Enrolled1,000ConditionsCOVID-19, Vaccine Reaction, Liver Diseases
3 · Its place in the literature

Who cites it

166 citing papers in PubMed, 6 syntheses or guidelines pooled it, 293 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Article
  18. Review
  19. Article
  20. Article

106 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

48 authors at 20 institutions in 14 countries.

Shiv Kumar SarinDepartment of Hepatology and Liver Transplant, Institute of Liver and Biliary Sciences, New Delhi, 110070, India. shivsarin@gmail.com.ORCID http://orcid.org/0000-0002-0544-5610
Ashok ChoudhuryDepartment of Hepatology and Liver Transplant, Institute of Liver and Biliary Sciences, New Delhi, 110070, India.
George K LauHumanity and Health Clinical Trial Center, Hong Kong SAR, China.
Ming-Hua ZhengDepartment of Hepatology, NAFLD Research Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Dong JiHumanity and Health Clinical Trial Center, Hong Kong SAR, China.
Sherief Abd-ElsalamTropical Medicine and Infectious Diseases Department, Tanta University, Tanta, Egypt.
Jaeseok HwangKeimyung University Dongsan Hospital, Daegu, South Korea.
Xiaolong QiCHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, China.
Ian Homer CuaInstitute of Digestive and Liver Diseases, St. Luke's Medical Center, Global City, Philippines.
Jeong Ill SuhDepartment of Internal Medicine, Dongguk University Gyeongju Hospital, Gyeongju, South Korea.
Jun Gi ParkDepartment of Internal Medicine, Dongguk University Gyeongju Hospital, Gyeongju, South Korea.
Opass PutcharoenDivision of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and Thai Red Cross, Bangkok, Thailand.
Apichat KaewdechGastroenterology and Hepatology Unit, Department of Medicine, Prince of Songkla University, Songkhla, Thailand.
Teerha PiratvisuthGastroenterology and Hepatology Unit, Department of Medicine, Prince of Songkla University, Songkhla, Thailand.
Sombat TreeprasertsukDivision of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and Thai Red Cross, Bangkok, Thailand.
Sooyoung ParkKyungpook National University Hospital, Daegu, South Korea.
Salisa WejnaruemarnDivision of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and Thai Red Cross, Bangkok, Thailand.
Diana A PayawalDepartment of Internal Medicine, Fatima University Medical Center, Valenzuela, Philippines.
Oidov BaatarkhuuDepartment of Infectious Diseases, School of Medicine, Mongolian National University of Medical Sciences, Ulan Bator, Mongolia.
Sang Hoon AhnSeverance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
Chang Dong YeoSeverance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
Uzziel Romar AlonzoDepartment of Internal Medicine, Fatima University Medical Center, Valenzuela, Philippines.
Tserendorj ChinbayarNational Center for Communicable Diseases, Ulan Bator, Mongolia.
Imelda M LohoDepartment of Gastroenterology and Hepatology "Dharmais", National Cancer Hospital, Jakarta, Indonesia.
Osamu YokosukaChiba University, Chiba, Japan.
Wasim JafriDepartment of Medicine, WGO Training Center, Aga Khan University, Karachi, Pakistan.
Soeksiam TanDepartment of Hepatology, Selayang Hospital, Batu Caves, Malaysia.
Lau Ing SooDepartment of Hepatology, Selayang Hospital, Batu Caves, Malaysia.
Tawesak TanwandeeDivision of Gastroenterology, Department of Medicine, Faculty of Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Rino GaniDivision of Hepatobiliary, Cipto Mangunkusuamo Hospital, University of Indonesia, Jakarta, Indonesia.
Lovkesh AnandHepatologist, Manipal Hospital, New Delhi, India.
Eslam Saber EsmailTropical Medicine and Infectious Diseases Department, Tanta University, Tanta, Egypt.
Mai KhalafTropical Medicine and Infectious Diseases Department, Tanta University, Tanta, Egypt.
Shahinul AlamDepartment of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.
Chun-Yu LinDivision of Infectious Diseases, School of Medicine, Kaohsiung Medical University, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Wan-Long ChuangDivision of Infectious Diseases, School of Medicine, Kaohsiung Medical University, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
A S SoinLiver Transplant Surgery, Medanta, The Medicity, Gurugram, Haryana, India.
Hitendra K GargHepatologist and Gastroenterologist, Indraprastha Apollo Hospital, New Delhi, India.
Kemal KalistaFaculty of Medicine, Cipto Mangunkusumo Hospitall, Universitas, Jakarta, Indonesia.
Badamnachin BatsukhDepartment of Infectious Diseases, School of Medicine, Mongolian National University of Medical Sciences, Ulan Bator, Mongolia.
Hery Djagat PurnomoKariadi Hospital, Diponegoro University, Semarang, Indonesia.
Vijay Pal DaraYerevan Medical University, Yerevan, Armenia.
Pravin RathiDepartment of Gastroenterology, T.N. Medical College, B.Y.L. Nair. Ch. Hospital, Mumbai, India.
Mamun Al MahtabDepartment of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.
Akash ShuklaDepartment of Gastroenterology, Seth GSMC and KEM Hospital, Mumbai, India.
Manoj K SharmaDepartment of Hepatology and Liver Transplant, Institute of Liver and Biliary Sciences, New Delhi, 110070, India.
Masao OmataDepartment of Gastroenterology, Yamanashi Prefectural Central Hospital, Kofu, Yamanashi, Japan.
APASL COVID Task Force, APASL COVID Liver Injury Spectrum Study (APCOLIS Study-NCT 04345640)
Institute of Liver and Biliary Sciences · INTanta University Hospital · EGThai Red Cross Society · THBangladesh Medical University · BDDongguk University · KRHospital Selayang · MYHumanity & Health · CNKaohsiung Medical University · TWMongolian National University of Medical Sciences · MNOur Lady of Fatima University · PHPrince of Songkla University · THYonsei University · KRAga Khan University · PKChiba University · JPDharmais Cancer Hospital · IDDiponegoro University · IDFirst Hospital of Lanzhou University · CNIndraprastha Apollo Hospitals · INKeimyung University · KRKing Edward Memorial Hospital and Seth G.S. Medical College · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsCOVID-19 is a dominant pulmonary disease, with multisystem involvement, depending upon comorbidities. Its profile in patients with pre-existing chronic liver disease (CLD) is largely unknown. We studied the liver injury patterns of SARS-Cov-2 in CLD patients, with or without cirrhosis.

methodsData was collected from 13 Asian countries on patients with CLD, known or newly diagnosed, with confirmed COVID-19.

resultsAltogether, 228 patients [185 CLD without cirrhosis and 43 with cirrhosis] were enrolled, with comorbidities in nearly 80%. Metabolism associated fatty liver disease (113, 61%) and viral etiology (26, 60%) were common. In CLD without cirrhosis, diabetes [57.7% vs 39.7%, OR = 2.1 (1.1-3.7), p = 0.01] and in cirrhotics, obesity, [64.3% vs. 17.2%, OR = 8.1 (1.9-38.8), p = 0.002] predisposed more to liver injury than those without these. Forty three percent of CLD without cirrhosis presented as acute liver injury and 20% cirrhotics presented with either acute-on-chronic liver failure [5 (11.6%)] or acute decompensation [4 (9%)]. Liver related complications increased (p < 0.05) with stage of liver disease; a Child-Turcotte Pugh score of 9 or more at presentation predicted high mortality [AUROC 0.94, HR = 19.2 (95 CI 2.3-163.3), p < 0.001, sensitivity 85.7% and specificity 94.4%). In decompensated cirrhotics, the liver injury was progressive in 57% patients, with 43% mortality. Rising bilirubin and AST/ALT ratio predicted mortality among cirrhosis patients.

conclusionsSARS-Cov-2 infection causes significant liver injury in CLD patients, decompensating one fifth of cirrhosis, and worsening the clinical status of the already decompensated. The CLD patients with diabetes and obesity are more vulnerable and should be closely monitored.

Indexed as

Acute-On-Chronic Liver FailureCoronavirus InfectionsLiver CirrhosisPandemicsPneumonia, ViralAsiaBetacoronavirusCOVID-19Disease ProgressionFemaleHumansLiver Function TestsMaleMiddle AgedPatient AcuityPrognosisAcute liver injuryChronic liver diseaseCOVID-19SARS CoV2

Identifiers

PMID32623632
PMCPMC7334898
OpenAlexW3038175434

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.